VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Okada Discusses Immunotherapy Response Assessment in Neuro-Oncology

Hideho Okada MD, PhD
Published: Sunday, Nov 22, 2015

Hideho Okada MD, PhD, professor, Neurological Surgery, University of California, San Francisco, discusses the need for a new immunotherapy response assessment in neuro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

As immunotherapy emerges in this field, physicians and researchers have noticed new types of challenges with interpretation of MRI images. After the initiation of therapy, a patient’s tumor will sometimes grow before shrinking. In many cases, Okada says, this leads to a premature termination of treatment.

Immunotherapies sometimes create an inflammatory response in the brain that makes the tumor look larger than it actually is, Okada says. This reinforces the need for new response criteria that are suitable for immunotherapy.

<<< View more from the 2015 SNO Meeting

Hideho Okada MD, PhD, professor, Neurological Surgery, University of California, San Francisco, discusses the need for a new immunotherapy response assessment in neuro-oncology. Okada presented on this topic at the 2015 Annual Meeting of the Society for Neuro-Oncology.

As immunotherapy emerges in this field, physicians and researchers have noticed new types of challenges with interpretation of MRI images. After the initiation of therapy, a patient’s tumor will sometimes grow before shrinking. In many cases, Okada says, this leads to a premature termination of treatment.

Immunotherapies sometimes create an inflammatory response in the brain that makes the tumor look larger than it actually is, Okada says. This reinforces the need for new response criteria that are suitable for immunotherapy.

<<< View more from the 2015 SNO Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x